Valeant Pharmaceutic
VRX
End-of-day quote Toronto Stock Exchange - 02/21
23.6CAD
+0.51%
Prev.23.4800
Open23.7500
High24.0600
Low23.6000
Volume865 708
Last news
Financials
Sales 2017 8 745 M
EBIT 2017 3 319 M
R. net 2017 -316 M
Debt 2017 25 281 M
Rend. 2017 -
P/E ratio 2017 3,69
P/E ratio 2018
EV / Sales 2017 3,63x
EV / Sales 2018 3,55x
Capitalization 6 471 M
Company
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a broad range of pharmaceutical products in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.It operates through the following segments: The Bausch +...
Sector :
Pharmaceuticals - NEC
Calendar :
2018-02-28 Earnings Release
Trading Rating :
Investor Rating :
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBullishBullish
Resistance26,230,329,7
Spread/Res.-9,9%-22%-21%
Spread/Supp.9,7%9,7%30%
Support21,521,518,1